Journals / Turkish Thoracic Journal / 2021 / Cilt: 22 - Sayı: 5

Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results

Pages
376–380
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

OBJECTIVE: Aspirin desensitization is recommended for patients with nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity, in whom asthma is uncontrolled despite medical treatment, and/or frequent endoscopic sinus surgery (ESS) is required due to nasal polyps.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Aspirin desensitization is recommended for patients with nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity, in whom asthma is uncontrolled despite medical treatment, and/or frequent endoscopic sinus surgery (ESS) is required due to nasal polyps.
📊
Key Findings & Data:This study aims to evaluate the effect of regular aspirin treatment on respiratory function, symptom control, quality of life, and the number of nasal surgeries required during a period of 12 years.
💡
Conclusion & Impact:CONCLUSION: Long-term regular treatment with aspirin at a dose of 300 mg/day in patients with N-ERD improved symptom scores, and alleviated the need for ESS due to nasal polyp recurrence.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Özet

OBJECTIVE: Aspirin desensitization is recommended for patients with nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity, in whom asthma is uncontrolled despite medical treatment, and/or frequent endoscopic sinus surgery (ESS) is required due to nasal polyps. There are few studies in the literature on long-term follow-up of patients undergoing regular aspirin treatment after desensitization. This study aims to evaluate the effect of regular aspirin treatment on respiratory function, symptom control, quality of life, and the number of nasal surgeries required during a period of 12 years. MATERIAL AND METHODS: A total of 18 patients were included in the study in 2006; 11 patients were excluded and 7 patients regularly taking aspirin for 12 years were evaluated. Oral aspirin desensitization was performed at 4-6 weeks following the ESS. Patients receiving 300 mg/day aspirin were followed up in control visits every 3 months. Nasal and respiratory system examinations and pulmonary function test were performed, and all patients responded to the SF-36 Quality of Life scale during each visit. RESULTS: There was no change in respiratory function parameters following the12-year aspirin treatment. There was no statistically significant improvement in the quality of life; however, the need for ESS due to the recurrence of nasal polyps decreased significantly (P = .000). At the 12-year follow-up, all symptom scores improved, but improvement in the postnasal drip score was statistically significant (P = .046). CONCLUSION: Long-term regular treatment with aspirin at a dose of 300 mg/day in patients with N-ERD improved symptom scores, and alleviated the need for ESS due to nasal polyp recurrence.

🔖

Cite This Article

KAYA, S. B., ÇAKMAK, M. E., ÇELEBİOĞLU, E., KARAKAYA, G., KALYONCU, A. F. (2021). Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results. Turkish Thoracic Journal, Cilt: 22 - Sayı: 5, 376–380. https://ajindex.com/articles/417259

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. White AA, Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018;379(11):1060-1070. [CrossRef] 2. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ. 2004;328(7437):434. [CrossRef] 3. Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID‐Exacerbated respiratory disease (N‐ERD)-a EAACI position paper. Allergy. 2019;74(1):28-39. [CrossRef] 4. Varghese M, Lockey RF. Aspirin-execerbated asthma. Allergy Asthma Clin Immunol. 2008;4(2):75-83. [CrossRef] 5. Walters KM, Waldram JD, Woessner KM, White AA. Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease. Am J Rhinol Allergy. 2018;32(4):280-286. [CrossRef] 6. Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575-581. [CrossRef] 7. Berges-Gimeno MP, Simon R A, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003;111(1):180-186. [CrossRef] 8. Kowalski ML, Wardzyńska A, Makowska JS. Clinical trials of aspirin treatment After desensitization in aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am. 2016;36(4):705-717. [CrossRef] 9. Ibrahim C, Singh K, Tsai G, et al. A retrospective study of the clinical benefit from acetylsalicylic acid desensitization in patients with nasal polyposis and asthma. Allergy Asthma Clin Immunol. 2014;10(1):64. [CrossRef] 10. Gosepath J, Schaefer D, Amedee RG, Mann WJ. Individual monitoring of aspirin desensitization. Arch Otolaryngol Head Neck Surg. 2001;127(3):316-321. [CrossRef] 11. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy. 2008;63(9):1228- 1234. [CrossRef] 12. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirinexacerbated respiratory disease. J Allergy Clin Immunol. 2007;119(1):157-164. [CrossRef] 13. Macy E, Bernstein JA, Castells MC, et al. Aspirin Desensitization Joint Task Force. Aspirin challenge and desensitization for aspirin- exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol. 2007;98(2):172-174. [Cr